The Countercultural Origins of an Industry (Politics and Culture in Modern America)
University of Pennsylvania Press, 9780812220513, 273pp.
Publication Date: October 15, 2008
The seemingly unlimited reach of powerful biotechnologies and the attendant growth of the multibillion-dollar industry have raised difficult questions about the scientific discoveries, political assumptions, and cultural patterns that gave rise to for-profit biological research. Given such extraordinary stakes, a history of the commercial biotechnology industry must inquire far beyond the predictable attention to scientists, discovery, and corporate sales. It must pursue how something so complex as the biotechnology industry was born, poised to become both a vanguard for contemporary world capitalism and a focal point for polemic ethical debate.
In Biotech, Eric J. Vettel chronicles the story behind genetic engineering, recombinant DNA, cloning, and stem-cell research. It is a story about the meteoric rise of government support for scientific research during the Cold War, about activists and student protesters in the Vietnam era pressing for a new purpose in science, about politicians creating policy that alters the course of science, and also about the release of powerful entrepreneurial energies in universities and in venture capital that few realized existed. Most of all, it is a story about people--not just biologists but also followers and opponents who knew nothing about the biological sciences yet cared deeply about how biological research was done and how the resulting knowledge was used.
Vettel weaves together these stories to illustrate how the biotechnology industry was born in the San Francisco Bay area, examining the anomalies, ironies, and paradoxes that contributed to its rise. Culled from oral histories, university records, and private corporate archives, including Cetus, the world's first biotechnology company, this compelling history shows how a cultural and political revolution in the 1960s resulted in a new scientific order: the practical application of biological knowledge supported by private investors expecting profitable returns eclipsed basic research supported by government agencies.